SERUM A1-ANTITRYPSIN LEVELS IN PROSTATE PATHOLOGY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The serum α1-antitrypsin (AAT) levels were determined using enzyme-linked immunosorbent assay (ELISA) and turbidimetry in patients with prostate cancer, patients with benign prostatic hyperplasia and healthy volunteers. Both methods revealed a significant increase of serum AAT levels in patients with prostate cancer compared with patients with BPH and healthy men. ELISA, as used in study, was more sensitive to changes in the concentration of AAT, but the sensitivity of the turbidimetry allows to use this method in the early diagnosis of prostate cancer.

Full Text

Restricted Access

About the authors

A. A Dokrunova

O. S Sokolova

References

  1. Silverberg E., Boring C. C., Squires T. S. Cancer Statistics. CA Cancer J. Clin. 1990;40:9-26.
  2. Stamey T. A., Yang N., Hay A. R. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 1987;317:909-916.
  3. Stamey T. A., Caldwell M., McNeal J. E. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years. Urol. 2004;172:1297-1301.
  4. Luisetti M., Seersholm N. Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax. 2004;59(2):164—169.
  5. Owen M. C., Brennan S. O., Lewis J. H. et al. Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N. Engl. J. Med. 1983;309(12):694-698.
  6. Perlmutter D. H., Cole F. S., Kilbridge P. et al. Expression of the alpha 1-proteinase inhibitor gene in human monocytes and macrophages. Proc. Natl. Acad. Sci. USA. 1985;82(3):795-799.
  7. Sun Z., Yang P. Role in imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol. 2004;5:82-190.
  8. Taggart C., Cervantes-Laurean D., Kim G. et al. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J. Biol Chem. 2000;275(35):27258-27265.
  9. Dabrowska M., Mantur M., Panasiuk A. et al. Does the concentration of alpha 1-proteinase inhibitor reflect the transformation of liver cirrhosis to liver carcinoma? Neoplasma. 1997;44(5):305-307.
  10. Tan X. F., Wu S. S., Li S. P. et al. Alpha-1 antitrypsin is a potential biomarker for hepatitis B. Virol J. 2011;8:274.
  11. Biemond I., Goedhard J. G., Klasen E. C. et al. Alpha-1-antitrypsin phenotypes and serum concentrations in duodenal ulcer patients in The Netherlands. Digestion. 1988;39(1):20-25.
  12. Sparos L., Tountas Y., Chapuis-Cellier C. et al. Alpha 1-antitrypsin levels and phenotypes and hepatitis B serology in liver cancer. Br. J. Cancer 1984;49(5):567-570.
  13. Tountas Y., Sparos L., Theodoropoulos C. et al. Alpha1-antitrypsin and cancer of the pancreas. Digestion. 1985; 31(1): 37-40.
  14. Daddi G., Mancini P. A., Parola D. et al. Alfa-antitrypsin increase in lung cancer. Boll ist Sieroter Mila. 1976;55(6):510-512.
  15. Dumitraşcu D., Radu D., Stanciu L. et al. Alpha 1-antitrypsin, alpha 2-macroglobulin and reactive protein C in gastric cancer. Rev MedInterna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1989;41(1):57-61.
  16. Krecicki T., Leluk M. Acute phase reactant proteins-an aid to monitoring surgical treatment of laryngeal carcinoma. J. Laryngol Otol. 1992;106(7):613—615.
  17. Amiguet J. A., Jiménez J., Monreal J. I. et al. Serum proteolytic activities and ntiproteases in human colorectal carcinoma. J. Physiol. Biochem. 1998;54(1):9—13.
  18. Mattison P., Cove D. H., Walsh L. et al. Serum proteins as tumour markers for breast cancer. Br. J. Cancer. 1981;43(4):542—545.
  19. Latner A. L., Turner G. A., Lamin M. M. Plasma alpha-1-antitrypsin levels in early and late carcinoma of the cervix. Oncology. 1976;33(1):12—14.
  20. Huang H., Campbell S. C., Nelius T. et al. Alpha1-antitrypsin inhibits angiogenesis and tumor growth. Int. J. Cancer. 2004; 112(6):1042—1048.
  21. Докрунова А. А., Уласова Н. Ю., Крамина Т. Е. и др. Полиморфизм α1-антитрипсина при раке и гиперплазии предстательной железы. Молекулярная медицина. 2010; 6:43—49.
  22. El-Akawi Z. J., Al-Hindawi F. K., Bashir N. A. Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients. Neuro. Endocrinol. Lett. 2008;29(4):482—484.
  23. Pirisi M., Fabris C., Soardo G. et al. Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma. Eur. J. Cancer. 1996;32A(2):221—225.
  24. Li Y., Krowka M. J., Qi Y. et al. Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival. J. Thorac. Oncol. 2011;6(2):291-295.
  25. Karashima S., Kataoka H., Itoh H. et al. Prognostic significance of alpha-1-antitrypsin in early stage of colorectal carcinomas. Int. J. Cancer 1990;45(2):244-250.
  26. Kataoka H., Seguchi K., Inoue T. et al. Properties of alpha 1-antitrypsin secreted by human adenocarcinoma cell lines. FEBS Lett. 1993;328(3):291-295.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies